RxDoctor Payments Data

Daven Chun, MD

Sports Medicine · Honolulu, HINPI 1477544468

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 19 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 5 manufacturers reported payments, led by Amarin Pharma, Inc. at 36.7% of the total. Reporting peaked in 2020 at $127 and has fallen 85.9% since, to $18 in 2025. That places this record below the midpoint for sports medicine clinicians in HI, where the typical reported total is $628.

$349in general payments, 2019–2025

Across 19 payments — averaging $18.39 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amarin Pharma, Inc.$128
  • Lilly USA, LLC$111
  • Boehringer Ingelheim$63
  • Novo Nordisk$29
  • AstraZeneca$18

What the payments were for

  • Food & beverage$349100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$349 in reported general payments places this provider in the 40th percentile of 31 sports medicine providers in Hawaii.

See all sports medicine providers in Hawaii

Medicare billing

Part B allowed, 2024
$180,343
Medicare patients
188
Services billed
2,829

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin111$163,648
Synjardy XrEmpagliflozin/Metformin Hcl44$71,114
TrulicityDulaglutide34$57,033
OzempicSemaglutide25$50,167
MounjaroTirzepatide31$41,912
RybelsusSemaglutide14$37,670
Trelegy ElliptaFluticasone/Umeclidin/Vilanter30$32,992
ProliaDenosumab17$28,836
JanuviaSitagliptin Phosphate18$25,495
XareltoRivaroxaban18$24,671
EliquisApixaban13$20,265
GlyxambiEmpagliflozin/Linagliptin12$19,990
Breo ElliptaFluticasone/Vilanterol16$15,909
SynjardyEmpagliflozin/Metformin Hcl18$15,499
Atorvastatin Calcium335$11,577

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance, Synjardy Xr, Glyxambi, Synjardy$63$270,251185 claims
Lilly USA, LLCTrulicity, Mounjaro$111$98,94565 claims
Novo NordiskOzempic, Rybelsus$29$87,83739 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 40th percentile of 31 sports medicine providers in Hawaii.

Other sports medicine in Honolulu

See the full list for Hawaii

Where these figures come from

Is this you, or does something look wrong? →